Opinion|Videos|July 29, 2024
Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors
A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What is the impact of dose modifications or interruptions on treatment outcomes with CDK4/6 inhibitors in the adjuvant setting?
- What has your experience been with toxicities and their management impacting patient adherence to CDK4/6 inhibitors in the adjuvant setting, and what strategies have you used to help improve this?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
3
Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis
4
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
5